Puma Biotechnology, Inc. (PBYI)

Puma Biotechnology's stock has experienced significant movement over the past six months, increasing by 76.09% as of November 4, 2025. Key financial events included a Q1 2025 net income of $3 million and Q2 2025 revenues of $52.4 million. The stock's 52-week range has been between $2.58 and $7.29. Recent stock price movements include a price target increase to $5.10 and a decrease to $3.57. Insider selling activity was noted, and Puma Biotechnology was added to the NASDAQ Biotechnology Index on December 22, 2025. Short interest in the company recently increased by 4.25%.

Puma Biotechnology's product sales exhibit some seasonality, with the first quarter typically being the lowest revenue quarter due to inventory drawdowns at specialty pharmacies and distributors following the holiday periods.

Puma Biotechnology is focused on developing and commercializing innovative products to enhance cancer care, operating in the Healthcare/Health Technology sector. The company acquires and develops cancer treatments, primarily through in-licensing. Its main product is NERLYNX, approved for HER2-overexpressed/amplified breast cancer and in combination with capecitabine for advanced HER2-positive breast cancer. Puma Biotechnology is also developing alisertib for various cancers.

Puma Biotechnology operates in the United States and internationally. NERLYNX is marketed in the United States and has European Commission authorization. The company has expanded globally through licensing agreements with partners like Pierre Fabre and CANbridge Life Sciences.

Specific events impacting Puma Biotechnology's brand reputation were not prominently highlighted. MarketBeat's evaluation placed Puma Biotechnology higher than 48% of companies and ranked it 582nd out of 872 stocks in the medical sector. The company has received a consensus rating of "Moderate Buy" from analysts.

Puma Biotechnology has a diverse ownership structure, with approximately 25.89% institutionally owned, 16.12% by insiders, and 57.99% by public companies and individual investors. Major institutional shareholders include Acorn Capital Advisors, Vanguard Group Inc, and BlackRock, Inc. Alan Auerbach owns the most shares of Puma Biotechnology.